PDCD1 and neoplasm: PRJEB23709 included 158 tumor biopsies from 120 melanoma patients treated with anti-PD-1 monotherapy (nivolumab or pembrolizumab) or combined anti-PD-1 and anti-CTLA-4 (nivolumab or pembrolizumab combined with ipilimumab) [12].